Medpace Holdings Inc (MEDP) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The Phase 1/2 study “A Phase 1/2 Study of [18F]FPyQCP for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications” aims to test a new imaging tracer in several hard to treat cancers. It focuses on safety and how well the tracer spots tumors, which could improve diagnosis and treatment planning.
The study tests a drug called [18F]FPyQCP, used as a tracer in PET/CT scans rather than as a therapy. The tracer is designed to bind to fibroblast activation protein in tumors, helping doctors see cancer more clearly and possibly earlier.
This is an interventional trial with one treatment arm, so all patients receive the tracer and imaging. It is open label with no masking, meaning both doctors and patients know what is given, and the main goal is to judge its value as a diagnostic tool.
The trial is currently recruiting, showing active development. It was first submitted on February 10, 2026, and last updated on March 25, 2026, signaling fresh information, though key dates for primary and final completion are not yet posted and will be important future catalysts.
For investors, this update highlights Blue Earth Diagnostics and Medpace, Inc. as key players in next generation cancer imaging. Success could support higher valuations for imaging specialists and benefit MEDP through more complex trial work, while also adding competitive pressure in the broader oncology imaging field.
The study remains ongoing and updated, with further details available on the ClinicalTrials portal.
To learn more about MEDP’s potential, visit the Medpace Holdings Inc drug pipeline page.